Liver Transplant Tested for Advanced Bile Duct Cancer Inside the Liver
Tests liver transplant in adults with advanced bile duct cancer controlled on chemotherapy.
Plain-language title generated from the registry record
Registry title: Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- University Health NetworkToronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT04195503
- Record updated
- 2 October 2026
- Original description
Diagnosis of intrahepatic cholangiocarcinoma (iCCA) is an increasingly common form of primary liver cancer, but patients with this diagnosis are not currently eligible for LT. This study proposes to offer LT as an option to patients with advanced, unresectable iCCA who demonstrate at least 6 months of disease stability /regression while receiving standard chemotherapy. Patients will be referred and screened for study participation if they have achieved 6 months of disease stability.Read full original descriptionShow less
Liver Transplantation in Locally- Advanced, Unresectable, Non-Metastatic Intrahepatic Cholangiocarcinoma Treated With Neoadjuvant Systemic Therapy: A Single-centre, Pilot Study
Diagnosis of intrahepatic cholangiocarcinoma (iCCA) is an increasingly common form of primary liver cancer, but patients with this diagnosis are not currently eligible for LT. This study proposes to offer LT as an option to patients with advanced, unresectable iCCA who demonstrate at least 6 months of disease stability /regression while receiving standard chemotherapy. Patients will be referred and screened for study participation if they have achieved 6 months of disease stability.
They will be worked up for transplant and if eligible, will be listed. Disease must remain controlled while awaiting transplantation. After transplantation, patients will be followed for disease recurrence and overall survival, while receiving standard post-transplantation followup.
Inclusion: Male or female, aged 18 years or older, at time of consent; Eastern Cooperative Oncology Group (ECOG) score : 0 or 1 at all times from study entry to LT; Able and willing to provide written informed consent; Women of child-bearing potential must agree to use adequate birth control; Histologically-confirmed diagnosis of iCCa; Disease is deemed unresectable based on tumor location or underlying liver dysfunction; No vascular invasion, extra-hepatic disease, or lymph node involvement detected on imaging; Patients must have ≥ 6 months of disease stability or tumor regression on gemcitabine-based therapy. For patients who have progressed to second-line therapy, disease must also be controlled for ≥ 6 months on that regimen; At least 1 living donor has stepped forward, is blood group compatible and has completed a "Health History form" which, upon review by the Living Donor team, is deemed acceptable and demonstrates no obvious contraindications to donation.
Exclusion: Previous or concurrent cancer (some exceptions permitted); Patients who have extrahepatic metastases, lymph node involvement, invasion or encasement of major hepatic vascular structures, perforation of the visceral peritoneum, invasion of extrahepatic structures, invasion of perihilar fat, periductular invasion, concurrent hepatoma or mixed hepatocellular cholangiocarcinoma; Patients having received prior locoregional therapies or radiation to the tumor; Prior history of solid organ or bone marrow transplantation; Known history of human immunodeficiency virus (HIV) infection; Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results; Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study; Renal dysfunction with an estimated creatinine clearance of less than 50 ml/min; Pregnant or breast-feeding patients (unless willing to abstain from breast-feeding).